Skip to content
Medical Health Aged Care

New industry-research partnership accelerates Medtech innovation in Melbourne

RMIT University 2 mins read

Australian medical device company Signature Orthopaedics is partnering with leading Medtech researchers at the University of Melbourne and RMIT University. 

The three-way strategic partnership connects research excellence in the fields of biomedical engineering, health, medicine, technology development and design with one of Australia’s most innovative Medtech enterprises.  

Signature Orthopaedics CEO Declan Brazil said their focus would be collaborative R&D in specific areas of clinical and technological innovation. 

“Together we will develop a clinical test bed for new materials, designs and methods in orthopaedic implants and devices, and connect our joint talent to amplify scientific and industry leadership across Australia’s growing Medtech sector,” he said.  

“This partnership’s goal is to bring to market new and personalised medical implant technologies that can improve health outcomes and quality of life.” 

The partnership strengthens Melbourne’s position as an emerging hub for Medtech research, teaching, and commercialisation, as well as RMIT and the University of Melbourne’s roles as major players in the sector.  

It also complements considerable investments by the two universities, plus the Victorian Government, into Medtech training and skills development. 

Other joint initiatives to date include the Victorian Medtech Skills and Devices Hub and state-of-the-art facilities at the Aikenhead Centre for Medical Discovery (ACMD), which will be Australia’s premier biomedical engineering research translation centre opening in 2025. 

RMIT’s Distinguished Professor Milan Brandt, Technical Director of RMIT's Advanced Manufacturing Precinct, has a long history of collaboration with medical device manufacturers, including Signature Orthopaedics. 

"This partnership not only brings the three organisations closer in terms of research opportunities in healthcare but also has the potential to generate new medical products and processes of significant benefit to patients locally and globally,” he said. 

While the partners already have a strong track record of collaboration, the first projects under this new three-way partnership will be announced in coming months. 

Professor Peter Lee from the Department of Biomedical Engineering at the University of Melbourne, said those projects would be exemplars for how university researchers and students can collaborate on research that directly impacts people’s lives.  

“The advantages of working directly with implant manufacturers such as Signature Orthopaedics and with clinicians from hospitals at the early stages of the project are immense,” he said.  

“It enables us to identify the project's ‘pain points’ early and develop solutions to overcome them. Unlike the traditional idea of prototyping when technology is nearly finalised, this partnership will accelerate our research for clinical applications benefiting patients." 

Signature Orthopaedics – established in Sydney in 2009 by Dr Declan Brazil – is the only manufacturer of implantable orthopaedic devices in Australia.  

Rapid growth in demand for their products has led to the establishment of additional manufacturing and distribution facilities in Europe and North America.  

Signature Orthopaedics manufactures products under its own brand, as well as for other well-known brand devices including hip and knee joint replacements, spinal, osseointegration, osteosynthesis and soft tissue repair implants. 


Contact details:

Michael Quin

[email protected]

+61 499 515 417

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.